Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse

Neuroscience Letters

Volumn 400, Issue 3, 2006, Pages 262-266

  Jockers Scherübl, Maria C ^a   Rentzsch, Johannes ^a   Danker Hopfe, Heidi ^a   Radzei, Nicole ^a   Schürer, Falk ^a   Bahri, Sharif ^a   Hellweg, Rainer ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cannabis; Multiple substance abuse; Nerve growth factor; Neurotrophins; NGF; Schizophrenia

Indexed keywords

NERVE GROWTH FACTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; STATISTICAL ANALYSIS; SUBSTANCE ABUSE; TREATMENT OUTCOME; ADDICTION; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONVALESCENCE; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; NERVE GROWTH FACTOR; RECOVERY OF FUNCTION; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 33747192052     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.02.056     Document Type: Article

References (26)

1. Aloe L., Ianitelli A., Bersani G., Alleva E., Angelucci F., Maselli P., and Manni L. Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Neuropsychobiology 36 (1997) 65-68
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth ed. (1994), American Psychiatric Press, Washington, DC
3. Andreasson S., Allebeck P., Engstrom A., and Rydberg U. Cannabis schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2 (1987) 1483-1485
4. Chiaretti A., Piastra M., Polidori G., Di Rocco C., Caresta E., Antonelli A., Amendola T., and Aloe L. Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury. Intensive Care Med. 29 (2003) 1329-1338
5. Ehrenreich H., Rinn T., Kunert H.J., Moeller M.R., Poser W., Schilling L., Gigerenzer G., and Hoehe M.R. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl.) 142 (1999) 295-301
6. Hellweg R., Hock C., and Hartung H.D. An improved and highly sensitive enzyme immunoassay for nerve growth factor, Technique. J. Methods Cell Mol. Biol. 1 (1989) 43-49
7. Iversen L. Cannabis and the brain. Brain 126 (2003) 1252-1270
8. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.-P., Bai G., and Zhang X. Cannabioids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 115 (2005) 3104-3116
9. Jockers-Scherübl M.C., Danker-Hopfe H., Mahlberg R., Selig F., Rentzsch J., Schürer F., Lang U.E., and Hellweg R. Brain-derived neurotrophic factor serum concentrations are increased in drug-naïve schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci. Lett. 371 (2004) 79-83
10. Jockers-Scherübl M.C., Matthies U., Danker-Hopfe H., Lang U.E., Mahlberg R., and Hellweg R. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J. Psychopharmacol. 17 (2003) 439-445
11. Johanson C.E., Duncan J.A., Stopa E.G., and Baird A. Enhanced prospects for drug-delivery and brain targeting by the choroid plexus CSF-route. Pharm. Res. 22 (2005) 1011-1037
12. Kang H., and Schuman E.M. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 267 (1995) 1658-1662
13. Karege F., Bondolfi G., Gervasoni N., Schwald M., and Aubry J.-M. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol. Psychiatry 57 (2005) 1068-1072
14. Karege F., Schwald M., and Cisse M. Postnatal development profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 328 (2002) 261-264
15. Lang U.E., Gallinat J., Danker-Hopfe H., Bajbouj M., and Hellweg R. Nerve growth factor serum concentrations in healthy human volunteers: physiological variance and stability. Neurosci. Lett. 344 (2003) 13-16
16. Lang U.E., Gallinat J., Kuhn S., Jockers-Scherübl M.C., and Hellweg R. Nerve growth factor and smoking cessation. Am. J. Psychiatry 159 (2002) 674-675
17. Lang U.E., Jockers-Scherübl M.C., and Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J. Neural. Transm. 111 (2004) 387-411
18. Lu B., Pang P.T., and Woo N.H. The Yin and Yang of neurotrophin action. Nat. Rev. Neurosci. 6 (2005) 603-614
19. Marenco S., and Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol. 12 (2000) 501-527
20. Margolese H.C., Malchy L., Negrete J.C., Tempier R., and Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr. Res. 67 (2004) 157-166
21. Pan W., Banks W.A., Fasold M.B., Bluth J., and Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37 (1998) 1553-1561
22. Parikh V., Evans D.R., Khan M.M., and Mahadik S.P. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr. Res. 60 (2003) 117-123
23. Sarne Y., and Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 677-884
24. Shoval G., and Weizmann A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol. 15 (2005) 319-329
25. Stirling J., Lewis S., Hopkins R., and White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 75 (2005) 135-137
26. Weinberger D.R. Cell biology of the hippocampal formation in schizophrenia. Biol. Psychiatry 45 (1999) 395-402